Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Rationale for combining ibrutinib with tisa-cel in MCL

Adrian Minson, MBBS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, explains the rationale for combining ibrutinib with tisagenlecleucel (tisa-cel) in mantle cell lymphoma (MCL), highlighting how ibrutinib can improve T-cell function. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Roche: Honoraria, Research Funding; Novartis: Other: Travel support, Research Funding.